Skip to main content

Table 6 Change in HbA1c as reported in the Cochrane evidence review

From: A cost-utility analysis of long-acting insulin analogues (detemir, glargine and degludec) for the treatment of adult type 1 diabetes in South Africa

Intervention

Comparator

Mean difference (IV, random, 95% CI)

Detemir

NPH

−0.03 [−0.14, 0.07] 

Glargine

NPH

−0.01 [−0.16, 0.13] 

Detemir

Glargine

−0.01 [−0.13, 0.12] (combined)

Degludec

Detemir

0.00 [−0.18, 0.18] 

Degludec

Glargine

0.11 [0.00, 0.21] 

  1. Reported values are for adult subgroup analysis. Where this subgroup analysis was not available, the analysis group is indicated in parentheses.
Back to article page

Cost Effectiveness and Resource Allocation

ISSN: 1478-7547

Contact us